MAPT and tauopathy: It was the first small molecule shown to be able to selectively degrade disease-associated mutant tau (A152T and P301L) in tauopathy patient iPSC-derived neuronal cell models in a manner that could be blocked by a neddylation inhibitor (MLN-4924), demonstrating dependency on the E3 ligase activity of CRL4, as well as by an inhibitor of the major protease activities of the proteasome (carfilzomib).